BACKGROUND: Common genetic variants in the insulin receptor substrate 1 (IRS1) gene have been recently associated with insulin resistance and hyperinsulinemia. We examined whether the best-associated variant modifies the long-term changes in insulin resistance and body weight in response to weight-loss diets in Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. METHODS AND RESULTS: We genotyped IRS1 rs2943641 in 738 overweight adults (61% were women) who were randomly assigned to 1 of 4 diets varying in macronutrient contents for 2 years. We assessed the progress in fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and weight loss by genotypes. At 6 months, participants with the risk-conferring CC genotype had greater decreases in insulin (P=0.009), HOMA-IR (P=0.015), and weight loss (P=0.018) than those without this genotype in the highest-carbohydrate diet group whereas an opposite genotype effect on changes in insulin and HOMA-IR (P≤0.05) was observed in participants assigned to the lowest-carbohydrate diet group. No significant differences were observed across genotypes in the other 2 diet groups. The tests for genotype by intervention interactions were all significant (P<0.05). At 2 years, the genotype effect on changes in insulin and HOMA-IR remained significant in the highest-carbohydrate diet group (P<0.05). The highest carbohydrate diet led to a greater improvement of insulin and HOMA-IR (P for genotype-time interaction ≤0.009) in participants with the CC genotype than those without this genotype across 2-year intervention. CONCLUSIONS:Individuals with the IRS1 rs2943641 CC genotype might obtain more benefits in weight loss and improvement of insulin resistance than those without this genotype by choosing a high-carbohydrate and low-fat diet. CLINICAL TRIAL REGISTRATION: http:www.clinicaltrials.gov. Unique identifier: NCT00072995.
RCT Entities:
BACKGROUND: Common genetic variants in the insulin receptor substrate 1 (IRS1) gene have been recently associated with insulin resistance and hyperinsulinemia. We examined whether the best-associated variant modifies the long-term changes in insulin resistance and body weight in response to weight-loss diets in Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. METHODS AND RESULTS: We genotyped IRS1rs2943641 in 738 overweight adults (61% were women) who were randomly assigned to 1 of 4 diets varying in macronutrient contents for 2 years. We assessed the progress in fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and weight loss by genotypes. At 6 months, participants with the risk-conferring CC genotype had greater decreases in insulin (P=0.009), HOMA-IR (P=0.015), and weight loss (P=0.018) than those without this genotype in the highest-carbohydrate diet group whereas an opposite genotype effect on changes in insulin and HOMA-IR (P≤0.05) was observed in participants assigned to the lowest-carbohydrate diet group. No significant differences were observed across genotypes in the other 2 diet groups. The tests for genotype by intervention interactions were all significant (P<0.05). At 2 years, the genotype effect on changes in insulin and HOMA-IR remained significant in the highest-carbohydrate diet group (P<0.05). The highest carbohydrate diet led to a greater improvement of insulin and HOMA-IR (P for genotype-time interaction ≤0.009) in participants with the CC genotype than those without this genotype across 2-year intervention. CONCLUSIONS: Individuals with the IRS1rs2943641 CC genotype might obtain more benefits in weight loss and improvement of insulin resistance than those without this genotype by choosing a high-carbohydrate and low-fat diet. CLINICAL TRIAL REGISTRATION: http:www.clinicaltrials.gov. Unique identifier: NCT00072995.
Authors: José López-Miranda; Pablo Pérez-Martínez; Carmen Marin; Francisco Fuentes; Javier Delgado; Francisco Pérez-Jiménez Journal: J Mol Med (Berl) Date: 2006-12-15 Impact factor: 4.599
Authors: Chunli Yu; Yan Chen; Gary W Cline; Dongyan Zhang; Haihong Zong; Yanlin Wang; Raynald Bergeron; Jason K Kim; Samuel W Cushman; Gregory J Cooney; Bronwyn Atcheson; Morris F White; Edward W Kraegen; Gerald I Shulman Journal: J Biol Chem Date: 2002-11-14 Impact factor: 5.157
Authors: Gary D Foster; Holly R Wyatt; James O Hill; Brian G McGuckin; Carrie Brill; B Selma Mohammed; Philippe O Szapary; Daniel J Rader; Joel S Edman; Samuel Klein Journal: N Engl J Med Date: 2003-05-22 Impact factor: 91.245
Authors: Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein Journal: Gastroenterology Date: 2009-01-25 Impact factor: 22.682
Authors: A Dresner; D Laurent; M Marcucci; M E Griffin; S Dufour; G W Cline; L A Slezak; D K Andersen; R S Hundal; D L Rothman; K F Petersen; G I Shulman Journal: J Clin Invest Date: 1999-01 Impact factor: 14.808
Authors: Christopher D Gardner; Alexandre Kiazand; Sofiya Alhassan; Soowon Kim; Randall S Stafford; Raymond R Balise; Helena C Kraemer; Abby C King Journal: JAMA Date: 2007-03-07 Impact factor: 56.272
Authors: Tao Huang; Yan Zheng; Adela Hruby; Donald A Williamson; George A Bray; Yiru Shen; Frank M Sacks; Lu Qi Journal: J Nutr Date: 2017-02-01 Impact factor: 4.798
Authors: Khadijeh Mirzaei; Min Xu; Qibin Qi; Lilian de Jonge; George A Bray; Frank Sacks; Lu Qi Journal: Am J Clin Nutr Date: 2013-12-11 Impact factor: 7.045
Authors: Xiaochen Lin; Qibin Qi; Yan Zheng; Tao Huang; Mark Lathrop; Diana Zelenika; George A Bray; Frank M Sacks; Liming Liang; Lu Qi Journal: Am J Clin Nutr Date: 2015-07-08 Impact factor: 7.045
Authors: Yoriko Heianza; Dianjianyi Sun; Tiange Wang; Tao Huang; George A Bray; Frank M Sacks; Lu Qi Journal: Diabetes Date: 2017-06-28 Impact factor: 9.461
Authors: Tao Huang; Qibin Qi; Yanping Li; Frank B Hu; George A Bray; Frank M Sacks; Donald A Williamson; Lu Qi Journal: Am J Clin Nutr Date: 2014-03-12 Impact factor: 7.045
Authors: Yan Zheng; Uta Ceglarek; Tao Huang; Tiange Wang; Yoriko Heianza; Wenjie Ma; George A Bray; Joachim Thiery; Frank M Sacks; Lu Qi Journal: J Clin Endocrinol Metab Date: 2016-07-28 Impact factor: 5.958